MERRIMACK PHARMACEUTICALS IN's ticker is MACKXXXX and the CUSIP is 590328100. A total of 153 filers reported holding MERRIMACK PHARMACEUTICALS IN in Q1 2015. The put-call ratio across all filers is 0.37 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $253,000 | +7.7% | 62,000 | +67.6% | 0.01% | -20.0% |
| Q3 2016 | $235,000 | +32.8% | 37,000 | +12.8% | 0.02% | +7.1% |
| Q2 2016 | $177,000 | -61.5% | 32,805 | -40.4% | 0.01% | -30.0% |
| Q1 2016 | $460,000 | +5.7% | 55,000 | 0.0% | 0.02% | -33.3% |
| Q4 2015 | $435,000 | +0.2% | 55,000 | +7.8% | 0.03% | +57.9% |
| Q3 2015 | $434,000 | +284.1% | 51,000 | +410.0% | 0.02% | +375.0% |
| Q4 2014 | $113,000 | -67.8% | 10,000 | -75.0% | 0.00% | -55.6% |
| Q3 2014 | $351,000 | +20.2% | 40,000 | 0.0% | 0.01% | +50.0% |
| Q2 2014 | $292,000 | -3.3% | 40,000 | -33.3% | 0.01% | 0.0% |
| Q1 2014 | $302,000 | -56.4% | 60,000 | -53.8% | 0.01% | -60.0% |
| Q4 2013 | $693,000 | +14.4% | 130,000 | -18.8% | 0.02% | +114.3% |
| Q3 2013 | $606,000 | +50.0% | 160,000 | +166.7% | 0.01% | -41.7% |
| Q2 2013 | $404,000 | – | 60,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lagoda Investment Management, L.P. | 2,211,880 | $17,474,000 | 4.63% |
| Parametrica Management Ltd | 21,228 | $168,000 | 1.11% |
| GARRISON BRADFORD & ASSOCIATES INC | 82,700 | $653,000 | 0.73% |
| Virtus ETF Advisers LLC | 33,570 | $265,000 | 0.73% |
| Opus Point Partners Management, LLC | 122,500 | $968,000 | 0.64% |
| NEXTHERA CAPITAL LP | 36,000 | $284,000 | 0.40% |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 7,255,815 | $57,321,000 | 0.39% |
| Cannell & Co. | 1,051,178 | $7,751,000 | 0.25% |
| Tekla Capital Management LLC | 853,787 | $6,745,000 | 0.24% |
| STONERIDGE INVESTMENT PARTNERS LLC | 208,282 | $1,645,000 | 0.22% |